[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Kurth AA, Kim SZ, Shea M, Bauss F, Hayes WC, Müller R: Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis. J Bone Miner Metab; 2007;25(2):86-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
  • Walker carcinosarcoma cells were implanted into the left femur of female rats that received 26-day ibandronate pretreatment followed by continued therapy or ibandronate posttreatment only.
  • At endpoint, excised femurs were scanned using microcomputed tomography (microCT) to assess bone volume density, bone mineral content, trabecular number/thickness, and separation for cortical plus trabecular bone or trabecular bone alone.
  • Compared with the nonimplanted right femur, bone volume and surface density and trabecular number and thickness were reduced in the distal left femur following tumor cell implantation. microCT analysis revealed greater cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate group, and the interventional (post-tumor) ibandronate group, versus the tumor-only group.
  • After preventative and interventional ibandronate, bone volume density and trabecular thickness were 13% and 60% greater, respectively, than in the post-tumor treatment group.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone and Bones / pathology. Carcinoma 256, Walker / pathology. Diphosphonates / therapeutic use
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Femur / drug effects. Femur / pathology. Image Processing, Computer-Assisted. Rats

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 May 15;99(10 ):2509-17 [9153295.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17 (7):1139-47 [12096826.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5452-7 [8221685.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 May;20(5):685-93 [6428894.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Phys Med Biol. 1994 Jan;39(1):145-64 [7651993.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2324-33 [8641182.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] J Bone Miner Res. 1994 Feb;9(2):221-30 [8140935.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Anat Rec. 1997 Dec;249(4):458-68 [9415453.001]
  • [Cites] Osteoporos Int. 2001;12 (11):936-41 [11804020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):126-30 [10697328.001]
  • [Cites] Bone. 2004 Apr;34(4):736-46 [15050906.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3080-8 [10898355.001]
  • [Cites] Osteoporos Int. 2004 Jun;15(6):423-33 [15205712.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Bone. 2002 Jan;30(1):300-6 [11792601.001]
  • [Cites] J Bone Miner Res. 2003 Nov;18(11):1932-41 [14606504.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Osteoporos Int. 1998;8(2):97-103 [9666930.001]
  • [Cites] Calcif Tissue Int. 1996 Jan;58(1):24-9 [8825235.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):91-8 [8508433.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] Mol Pharmacol. 1996 Nov;50(5):1127-38 [8913344.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1482-91 [8889848.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):468-77 [14506749.001]
  • [Cites] Osteoporos Int. 2002 Oct;13(10):816-23 [12378371.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1167-74 [10404017.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3007-11 [6233002.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(6):539-43 [3119600.001]
  • [Cites] J Orthop Res. 2001 Mar;19(2):200-5 [11347691.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(1):35-41 [3949849.001]
  • [Cites] Drugs. 2000 Mar;59(3):391-9 [10776826.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] Oncology. 1988;45(1):41-6 [3340393.001]
  • [Cites] J Bone Miner Res. 2004 Nov;19(11):1787-96 [15476578.001]
  • (PMID = 17323177.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; UMD7G2653W / ibandronic acid
  •  go-up   go-down


2. Mihalache D, Preoteasa V, Barca V: Effects of combined selenium and vitamin E administration on DNA in Walker tumor bearing Wistar rat exposed to cytostatic acute treatment. Roum Arch Microbiol Immunol; 2003 Jul-Dec;62(3-4):239-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of combined selenium and vitamin E administration on DNA in Walker tumor bearing Wistar rat exposed to cytostatic acute treatment.
  • Previous studies have showed that organic Se and Vitamin E have a significant protective effect when administered in combination with cytostatics.
  • This paper reports the investigation on effects of mixed administration Orgasel 50 and Vitamin E in Wistar rat with experimentally induced Walker tumor under acute cytostatic treatment, with emphasis on two aspects: a) the influence of antioxidants upon liver unscheduled DNA biosynthesis under cytostatic (Lomustin) acute aggression; and b) the potential improvement of cytostatic effects by antioxidants treatment in tumor.
  • The Walker tumor (an epithelial carcinoma) cells were subcutaneously injected (5 x 10(6) cells/0.5 ml in isotonic saline solution); the first tumor nodules appeared in 4 days; the tumor has reached the appropriate dimensions in 12 days.
  • The unscheduled DNA biosynthesis caused by Lomustin in rat liver as well as the replicative DNA biosynthesis taking place in Walker tumor cells were assessed radioisotopically by measuring the uptake of 3H-Thymidine (200 microCi / 100 g.b.w.).
  • Our observations regarding the role of antioxidant treatment suggest:.
  • The most significant results were showed in both analyzed tissues, when the Orgasel 50 + Vitamin E administration begins at the same time with the tumor cell inoculation.
  • These findings clearly show the organic Se salts and Vitamin E constitute a valuable adjuvant in anticancer medication, increasing the interest for the application of these antioxidants in cancer therapy and prevention.
  • [MeSH-major] Antioxidants / therapeutic use. Carcinoma 256, Walker / drug therapy. Selenium / therapeutic use. Selenium Compounds / therapeutic use. Vitamin E / therapeutic use. Yeast, Dried / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Drug Combinations. Drug Therapy, Combination. Injections, Intramuscular. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SELENIUM DISULFIDE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008147.001).
  • [ISSN] 1222-3891
  • [Journal-full-title] Roumanian archives of microbiology and immunology
  • [ISO-abbreviation] Roum Arch Microbiol Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Drug Combinations; 0 / Selenium Compounds; 0 / orgasel; 1406-18-4 / Vitamin E; 7488-56-4 / selenium disulfide; H6241UJ22B / Selenium
  •  go-up   go-down


3. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H, Okuno S: Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents. Biol Pharm Bull; 2000 May;23(5):621-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR.
  • Disposition characteristics of [3H]CMPul in rats bearing Walker 256 carcinosarcoma indicate that pullulan, which had molecular weight over 50 kDa, is a suitable macromolecular carrier for tumor targeting in cancer chemotherapy by carboxymethylation.
  • CMPul-DXR conjugates were also distributed in the reticuloendothelial organs, such as liver, spleen and bone marrow; however, the tissue concentrations of the conjugates in the heart, lung and muscle were lower than those of DXR.
  • We next investigated the effect of the DXR contents of CMPul-DXR conjugates on their body distribution in rats bearing Walker 256.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinosarcoma / metabolism. Doxorubicin / pharmacokinetics. Glucans / pharmacokinetics
  • [MeSH-minor] Animals. Carbohydrate Sequence. Female. Male. Mice. Molecular Sequence Data. Peptides / administration & dosage. Peptides / chemistry. Rats. Rats, Wistar. Tissue Distribution. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10823676.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucans; 0 / Peptides; 0 / carboxymethylpullulan; 10028-17-8 / Tritium; 80168379AG / Doxorubicin
  •  go-up   go-down


Advertisement
4. Tandon VK, Singh RV, Rai S, Chhor RB, Khan ZK: Synthesis and pharmacological studies of some 2-t-amino and 2,3-di-t-amino substituted 1,4-naphthoquinones and related compounds. Boll Chim Farm; 2002 Jul-Aug;141(4):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and pharmacological studies of some 2-t-amino and 2,3-di-t-amino substituted 1,4-naphthoquinones and related compounds.
  • [MeSH-minor] Animals. Anti-Bacterial Agents. Antifungal Agents / chemical synthesis. Antifungal Agents / pharmacology. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Antiviral Agents / chemical synthesis. Antiviral Agents / pharmacology. Bacteria / drug effects. Carcinoma 256, Walker / drug therapy. Drug Screening Assays, Antitumor. Fungi / drug effects. Indicators and Reagents. Microbial Sensitivity Tests. Viral Plaque Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12426819.001).
  • [ISSN] 0006-6648
  • [Journal-full-title] Bollettino chimico farmaceutico
  • [ISO-abbreviation] Boll Chim Farm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Indicators and Reagents; 0 / Naphthoquinones
  •  go-up   go-down


5. Gade TP, Koutcher JA, Spees WM, Beattie BJ, Ponomarev V, Doubrovin M, Buchanan IM, Beresten T, Zakian KL, Le HC, Tong WP, Mayer-Kuckuk P, Blasberg RG, Gelovani JG: Imaging transgene activity in vivo. Cancer Res; 2008 Apr 15;68(8):2878-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The successful translation of gene therapy for clinical application will require the assessment of transgene activity as a measure of the biological function of a therapeutic transgene.
  • Although current imaging permits the noninvasive detection of transgene expression, the critical need for quantitative imaging of the action of the expressed transgene has not been met.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2180-9 [10561274.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3738-47 [17575240.001]
  • [Cites] Nat Biotechnol. 2000 Mar;18(3):321-5 [10700150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5151-5 [10805778.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):315-20 [10935486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12278-82 [11050247.001]
  • [Cites] MAGMA. 2001 May;12(2-3):141-52 [11390270.001]
  • [Cites] NMR Biomed. 2001 Jun;14(4):278-83 [11410946.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9300-5 [11481488.001]
  • [Cites] Circulation. 2002 Jul 30;106(5):631-6 [12147548.001]
  • [Cites] Radiology. 2003 Oct;229(1):241-7 [12920178.001]
  • [Cites] Drug Discov Today. 2003 Nov 1;8(21):990-6 [14643162.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):616-20 [15004806.001]
  • [Cites] Magn Reson Med. 2004 Jul;52(1):169-73 [15236381.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jun;79(11):3523-6 [6954498.001]
  • [Cites] Biochim Biophys Acta. 1986 Apr 11;881(2):268-75 [3513846.001]
  • [Cites] Magn Reson Med. 1988 Jul;7(3):319-36 [3205148.001]
  • [Cites] Clin Chem. 1989 Mar;35(3):392-5 [2920404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):492-6 [2296605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(8):3112-6 [2326269.001]
  • [Cites] Magn Reson Med. 1991 May;19(1):113-23 [2046526.001]
  • [Cites] Magn Reson Imaging. 1991;9(4):621-5 [1664017.001]
  • [Cites] Magn Reson Imaging. 1992;10(3):471-85 [1406098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6733-7 [7624312.001]
  • [Cites] Radiology. 1996 Mar;198(3):795-805 [8628874.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4087-95 [8797571.001]
  • [Cites] NMR Biomed. 1996 Jun;9(4):141-55 [9015801.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1115-9 [9415319.001]
  • [Cites] Nat Med. 1998 Feb;4(2):245-7 [9461201.001]
  • [Cites] Breast Cancer Res Treat. 1997 Nov-Dec;46(2-3):303-12 [9478282.001]
  • [Cites] Nat Med. 1998 Jun;4(6):655-7 [9623964.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4075-8 [9751613.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):339-45 [9816177.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):375-8 [10207887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9821-6 [10449778.001]
  • [Cites] Nat Med. 2000 Mar;6(3):351-5 [10700241.001]
  • (PMID = 18413756.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA086438; United States / NCI NIH HHS / CA / R24 CA083084-03; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA083084-03; United States / NCI NIH HHS / CA / CA086438-07; United States / NCI NIH HHS / CA / P50 CA086438-07; United States / NCI NIH HHS / CA / P50CA86438; United States / NCI NIH HHS / CA / R24CA83084; United States / NCI NIH HHS / CA / R24 CA083084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 284SYP0193 / Fluorine
  • [Other-IDs] NLM/ NIHMS49923; NLM/ PMC3043616
  •  go-up   go-down


6. Levi M, DeRemer SJ, Dou C, Ensminger WD, Smith DE: Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine. Biopharm Drug Dispos; 2004 Jan;25(1):27-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Amifostine is a prodrug in which selectivity is largely determined by the preferential formation and uptake of its cytoprotective metabolite, WR-1065, in normal tissues as a result of differences in membrane-bound alkaline phosphatase activity.
  • It was hypothesized that amifostine may be a good candidate for regional drug delivery to the liver because of its large hepatic extraction and total body clearance.
  • METHODS: Rat livers were implanted with Walker-256 tumors.
  • WR-1065 concentrations in the blood, liver and tumor were measured at various times.
  • CONCLUSIONS: Amifostine may provide increased liver protection and decreased tumor protection from radio- or chemotherapy when administered by the portal vein.
  • [MeSH-major] Amifostine / administration & dosage. Amifostine / metabolism. Drug Delivery Systems / methods. Liver Neoplasms, Experimental / drug therapy. Mercaptoethylamines / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / surgery. Disease Models, Animal. Drug Screening Assays, Antitumor. Femoral Vein / drug effects. Infusions, Intravenous. Male. Neoplasm Transplantation / methods. Portal Vein / drug effects. Prodrugs / administration & dosage. Prodrugs / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 John Wiley & Sons, Ltd.
  • (PMID = 14716750.001).
  • [ISSN] 0142-2782
  • [Journal-full-title] Biopharmaceutics & drug disposition
  • [ISO-abbreviation] Biopharm Drug Dispos
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098502
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mercaptoethylamines; 0 / Prodrugs; 31098-42-7 / WR 1065; M487QF2F4V / Amifostine
  •  go-up   go-down


7. Rotinberg P, Kelemen S, Gramescu M, Rotinberg H, Nuta V: Preclinical qualitative evaluation of the antitumoral pharmacodynamic action of some natural polyphenolic biopreparations. Rom J Physiol; 2000 Jan-Dec;37(1-4):91-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of in vivo tests of their effect on the development of Guerin T-8 lymphotropic epithelioma and Walker 256 carcinosarcoma were conducted.
  • All those results highlighted the antineoplastic pharmacotherapeutic effect of the polyphenolic biopreparations and also proved that effect to be replicable.
  • The qualitative evaluation of the pharmacodynamic action of those preparations was a condition for their further quantitative pharmacological evaluation in point of antitumoral therapeutic effectiveness in a preclinical stage.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413150.001).
  • [ISSN] 1223-4974
  • [Journal-full-title] Romanian journal of physiology : physiological sciences
  • [ISO-abbreviation] Rom J Physiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polymers; 0 / Polyphenols
  •  go-up   go-down


8. Paterson AH: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer; 2000 Jun 15;88(12 Suppl):3038-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
  • Within the family of BPs there are more similarities in pharmacologic effects than differences, although side effect profiles, rates of oral absorption, and potency do differ.
  • Oral clodronate and intravenous pamidronate reduce skeletal complications in patients with bone metastases from breast carcinoma (as well as in myeloma).
  • Uncontrolled trials of prostate carcinoma also suggest clinical benefit.
  • METHODS: Animal studies show that BPs can reduce the rate of development of bone metastases (for example, in Walker 256 carcinoma), but there is little evidence of an effect at nonosseous sites.
  • RESULTS: In patients with recurrent breast carcinoma but no overt bone metastases, oral clodronate reduced the number of diagnosed bone metastases; but the number of patients who had relapses in bone, though smaller, was not significantly different from the number among patients who took placebo.
  • Patients treated for operable breast carcinoma have four or five times the normal rate of vertebral fracture, and BPs do reduce the rate of bone loss.
  • ), showed a reduction in osseous and nonosseous recurrences and an increase in disease free and overall survival with 2 years of clodronate.
  • A second open-label trial (Saarto et al.) of similar size involving lymph node positive breast carcinoma patients showed no effect on the rate of bone metastasis relapse and a deleterious effect on relapse rates of nonosseous metastases with 3 years of clodronate.
  • A third placebo-controlled trial involving 1079 patients reported, in an interim analysis, a reduction in osseous metastases during treatment with 2 years of clodronate, but no effect on nonosseous metastases or survival.
  • 1) scientifically, it is important to demonstrate that an agent that has its dominant effect on a normal tissue cell, the osteoclast, can influence the growth of neoplastic cells; and 2) from the perspective of patient care, it must be unequivocally shown that a reduction in the rate of osseous recurrence translates into an improvement in disease free survival or an improvement in quality of life through reduction of adverse skeletal events.
  • The National Surgical Adjuvant Breast Project has committed to conducting this study and including women with operable breast carcinoma.
  • [MeSH-major] Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Diphosphonates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Clinical Trials as Topic. Female. Humans. Spinal Fractures / etiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898349.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 62
  •  go-up   go-down


9. Cao F, Gao F, Xu AJ, Chen ZJ, Chen SS, Yang H, Yu HH, Mei W, Liu XJ, Xiao XP, Yang SB, Tian XB, Wang XR, Tian YK: Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain. Brain Res; 2010 Apr 22;1326:162-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain.
  • Although opioids remain the principal axis in drug therapies for CIBP, their sustained application is known to induce cellular and molecular adaptations including enhanced neuroimmune reactivity.
  • This is generally characterized by glial activation and proinflammatory cytokine production which frequently results in pharmacological tolerance.
  • This research was performed to investigate spinal neuroimmune responses after prolonged systemic morphine treatment in a rat model of CIBP.
  • The model was established using a unilateral intra-tibia injection of Walker 256 mammary gland carcinoma cells.
  • Spinal glial activation was detected by immunohistochemistry and real-time PCR; the production of proinflammatory cytokines (IL-1beta and TNF-alpha) was examined through real-time PCR and ELISA.
  • Moreover, the treatment had no significant influence on the activated spinal glia morphology, cell density and expression of special cytomembrane markers, whereas it significantly down-regulated the local proinflammatory cytokine production at the mRNA and protein level.
  • Collectively, these data suggest that chronic morphine treatment in CIBP is not concomitant with pharmacological tolerance, at least partially because the treatment fails to amplify spinal neuroimmune responses.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Gene Expression Regulation / drug effects. Interleukin-1beta / metabolism. Morphine / therapeutic use. Pain / drug therapy. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Animals. Antigens, CD11b / genetics. Antigens, CD11b / metabolism. Bone Neoplasms / complications. Carcinoma / pathology. Cell Line, Tumor. Disease Models, Animal. Enzyme-Linked Immunosorbent Assay / methods. Female. Glial Fibrillary Acidic Protein / metabolism. Hyperalgesia / drug therapy. Hyperalgesia / etiology. Mammary Neoplasms, Experimental. Neoplasm Transplantation. Neuroglia / drug effects. Neuroglia / metabolism. Pain Threshold / drug effects. Rats. Rats, Wistar. Spinal Cord / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20176002.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antigens, CD11b; 0 / Glial Fibrillary Acidic Protein; 0 / Interleukin-1beta; 0 / Tumor Necrosis Factor-alpha; 76I7G6D29C / Morphine
  •  go-up   go-down


10. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J: Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv; 2009 Jul;6(3):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Success of selective drug therapies depends on the drug's depot time in the target to treat.
  • Depot time is currently being prolonged, using drug-eluting beads or microspheres for selective internal radiation therapy.
  • The purpose of this study was to establish a model for investigating the depot time of particles injected into tumors in relation to tumor vascularization and particle size.
  • MATERIALS AND METHODS: An animal model with two different vascularized tumors (Walker Carcinoma 256 (hypervascularized) and Yoshida Sarcoma (hypovascularized)) was used.
  • Tumor activity was measured with a gamma camera at 10 min, 1h, 3h, 6h, 14h and 48h p.i.
  • Measurements were adjusted for decay times and then compared.
  • CONCLUSIONS: Particle stay time, biodistribution, and stability can be easily monitored as shown in this animal model.
  • Prolonged retention is independent of vascularization and particle size and appears to be sufficient for therapy.
  • [MeSH-minor] Animals. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / metabolism. Epinephrine / pharmacology. Female. Humans. Injections, Intralesional. Kidney / metabolism. Liver / metabolism. Lung / metabolism. Radioisotopes / chemistry. Rats. Rats, Wistar. Rhenium / chemistry. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / metabolism. Serum Albumin / chemistry. Spleen / metabolism. Sulfur / chemistry. Tissue Distribution / drug effects

  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604139.001).
  • [ISSN] 1567-2018
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Serum Albumin; 0 / rhenium sulfur colloid; 70FD1KFU70 / Sulfur; 7440-15-5 / Rhenium; YKH834O4BH / Epinephrine
  •  go-up   go-down


11. Nunes EA, Kuczera D, Brito GA, Bonatto SJ, Yamazaki RK, Tanhoffer RA, Mund RC, Kryczyk M, Fernandes LC: Beta-hydroxy-beta-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-kappaB expression. Nutr Res; 2008 Jul;28(7):487-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-hydroxy-beta-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-kappaB expression.
  • Cancer cachexia syndrome contributes to wasting and weight loss leading to inefficacy of anticancer therapy.
  • In this study, the anticatabolic agent beta-hydroxy-beta-methylbutyrate (HMB) was supplemented to adult Walker 256 tumor-bearing rats during 8 weeks aiming to determine if tumor burden could be reduced.
  • In conclusion, HMB supplementation, at a similar dose used in humans to increase muscle mass, caused antitumor and anticachectic effects, with tumor-cell nuclear factor-kappaB pathway participation, which might be a potential nutritional strategy in cancer therapy.
  • [MeSH-major] Cachexia / prevention & control. Carcinoma 256, Walker / pathology. NF-kappa B / analysis. Valerates / administration & dosage
  • [MeSH-minor] Animals. Cell Division / drug effects. Glycogen / analysis. Liver / chemistry. Male. Muscle, Skeletal / chemistry. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19083450.001).
  • [ISSN] 1879-0739
  • [Journal-full-title] Nutrition research (New York, N.Y.)
  • [ISO-abbreviation] Nutr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Valerates; 3F752311CD / beta-hydroxyisovaleric acid; 9005-79-2 / Glycogen
  •  go-up   go-down


12. Welchinskaya HV, Piecuszak B, Kovalenko EA, Sharykina NI, Getman KI, Podgorsky VS: Biological activity of bacterial lectins and their molecular complexes with heterocyclic bis-adducts. Mikrobiol Z; 2003 Sep-Oct;65(5):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was discovered that these substances apply to a few toxic preparations and have a expression antitumour action on the tumours: Walker carcinosarcoma 256, Pliss' lymphosarcoma and Sarcoma 45.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Heterocyclic Compounds / chemistry. Lectins / chemistry. Lectins / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Bacillus / chemistry. Benzimidazoles / chemistry. Carcinoma 256, Walker / drug therapy. Crown Ethers. Halothane / chemistry. Imidazoles / chemistry. Lethal Dose 50. Lymphoma, Non-Hodgkin / drug therapy. Mice. Rats. Sarcoma, Experimental / drug therapy. Uracil / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE .
  • Hazardous Substances Data Bank. BENZIMIDAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723158.001).
  • [ISSN] 1028-0987
  • [Journal-full-title] Mikrobiolohichnyĭ zhurnal (Kiev, Ukraine : 1993)
  • [ISO-abbreviation] Mikrobiol. Z.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Crown Ethers; 0 / Heterocyclic Compounds; 0 / Imidazoles; 0 / Lectins; 56HH86ZVCT / Uracil; 63J177NC5B / 18-crown-6; 7GBN705NH1 / imidazole; E24GX49LD8 / benzimidazole; UQT9G45D1P / Halothane
  •  go-up   go-down


13. Knox RJ, Burke PJ, Chen S, Kerr DJ: CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des; 2003;9(26):2091-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CB 1954: from the Walker tumor to NQO2 and VDEPT.
  • Unfortunately, for the treatment of human disease, this anti-tumor selectivity was seen only in certain rat tumors.
  • The bioactivation of CB 1954 in rat cells involves the aerobic reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NQO1 (DT-diaphorase).
  • A gene therapy-based approach for targeting cancer cells and making them sensitive to CB 1954 and related compounds has been developed.
  • VDEPT (gene-directed enzyme prodrug therapy) has been used to express an E. coli nitroreductase in tumor cells and human tumor cells transduced to express this enzyme are very sensitive to prodrugs activated by nitroreduction.
  • When active, NQO2 is 3000 times more effective than human DT-diaphorase in the reduction of CB 1954.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Aziridines / pharmacology. Carcinoma 256, Walker / enzymology. Genetic Therapy / methods. Prodrugs / pharmacology. Quinone Reductases / metabolism
  • [MeSH-minor] Animals. Cell Survival / drug effects. Escherichia coli / enzymology. Humans. Nitroreductases / genetics. Nitroreductases / metabolism. Rats. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529407.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aziridines; 0 / Prodrugs; 7865D5D01M / tretazicar; EC 1.6.99.- / NRH - quinone oxidoreductase2; EC 1.6.99.- / Quinone Reductases; EC 1.7.- / Nitroreductases
  • [Number-of-references] 98
  •  go-up   go-down


14. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X: Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol; 2003 Nov;9(11):2445-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study.
  • In this study, we examined the effect of TACE on angiogenesis and expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) and to assess their relevance to Walker-256 transplanted hepatoma.
  • METHODS: Male Wistar rats were inoculated with Walker-256 tumor in the left lobe of liver.
  • Sixty rats bearing walker-256 transplanted hepatoma were randomly divided into control group, arterial infusion group and TACE group.
  • MVD of the control group, chemotherapy group and chemoemoblization group was 80.84+/-24.24, 83.05+/-20.29 and 85.20+/-23.91 (F=0.193, P=0.873), respectively.
  • CONCLUSION: There has been little influence of lipiodol chemoembolization on the formation of tumor angiogenesis, but the development of neovascularization and expression of VEGF play important roles in establishment of collateral circulation and reconstruction of blood supply of residual cancer tissue.
  • [MeSH-major] Carcinoma 256, Walker / physiopathology. Chemoembolization, Therapeutic. Fibroblast Growth Factor 2 / metabolism. Liver Neoplasms, Experimental / physiopathology. Neovascularization, Pathologic / therapy. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14606073.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC4656518
  •  go-up   go-down


15. Calin MA, Gruia Ml, Herascu N, Coman T: The monitoring of the accumulation of protoporphyrin IX in Walker tumours by subcutaneous administration of delta-aminolevulinic acid. J Exp Ther Oncol; 2004 Oct;4(3):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The monitoring of the accumulation of protoporphyrin IX in Walker tumours by subcutaneous administration of delta-aminolevulinic acid.
  • Photodynamic therapy with protoporphyrin IX induced by delta-aminolevulinic acid (ALA) is mainly applied for the treatment of human superficial skin cancer.
  • In this paper we present our study on photodynamic therapy (PDT) of the implanted Walker tumours using subcutaneous administration of ALA to improve the availability of ALA in the skin.
  • The temporal behavior of PpIX fluorescence has shown a clear demarcation of tumoural zone depending on the post-administration time and the administrated concentration of the ALA solution.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Carcinoma 256, Walker / drug therapy. Photochemotherapy. Photosensitizing Agents / pharmacokinetics. Protoporphyrins / pharmacokinetics
  • [MeSH-minor] Animals. Injections, Subcutaneous. Rats. Rats, Wistar. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724844.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


16. DiResta GR, Lee J, Healey JH, Larson SM, Arbit E: Enhancing the uptake of chemotherapeutic drugs into tumors using an "artificial lymphatic system". Ann Biomed Eng; 2000 May;28(5):556-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the uptake of chemotherapeutic drugs into tumors using an "artificial lymphatic system".
  • This paper presents findings from uptake studies to evaluate the ability of an "artificial lymphatic system" (ALS) to enhance large and small molecular weight drug transport into solid tumors and the therapeutic effect of the additional drug on their growth.
  • Walker 256, Neuroblastoma, and Sarcoma dual-tumor models were used to evaluate the effect of ALS aspiration on the uptake of 3F8 monoclonal antibody, and doxorubicin.
  • A tumor shrinkage experiment using Walker 256 dual tumors was used to evaluate the efficacy of an implantable ALS with cyclophosphamide chemotherapy.
  • Drug uptake significantly increased in all aspirated tumors; 3F8 uptake was enhanced 37.4% in the Walker and 93.1% in the Neuroblastoma tumor lines (p<0.05).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Artificial Organs. Lymphatic System. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Biological Transport, Active. Biomedical Engineering. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Carcinoma 256, Walker / pathology. Cyclophosphamide / administration & dosage. Cyclophosphamide / pharmacokinetics. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Male. Neuroblastoma / drug therapy. Neuroblastoma / metabolism. Neuroblastoma / pathology. Rats. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / metabolism. Sarcoma, Experimental / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10925953.001).
  • [ISSN] 0090-6964
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01-CA78494-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


17. Tandon VK, Yadav DB, Chaturvedi AK, Shukla PK: Synthesis of (1,4)-naphthoquinono-[3,2-c]-1H-pyrazoles and their (1,4)-naphthohydroquinone derivatives as antifungal, antibacterial, and anticancer agents. Bioorg Med Chem Lett; 2005 Jul 1;15(13):3288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The structure-activity relationship of these compounds was studied and the results show that the compound 2b exhibited in vitro antifungal activity against Candida albicans and Cryptococcus neoformans, and also possessed antibacterial profile against Klebsiella pneumoniae and Escherichia coli whereas 1c showed anticancer activity against Walker 256 Carcinosarcoma in rats.
  • [MeSH-minor] Animals. Candida albicans / drug effects. Carcinoma 256, Walker / drug therapy. Cryptococcus neoformans / drug effects. Escherichia coli / drug effects. Klebsiella pneumoniae / drug effects. Microbial Sensitivity Tests. Naphthoquinones / pharmacology. Rats. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913995.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Naphthoquinones; 0 / Pyrazoles
  •  go-up   go-down


18. Qin XJ, He W, Hai CX, Liang X, Liu R: Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy. J Appl Toxicol; 2008 Apr;28(3):271-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy.
  • Although antioxidant treatment is a promising method to prevent the side effects, protection by a single antioxidant is limited.
  • A rat tumor model with a transplanted tumor in the liver was treated with adriamycin and ANTIOXIN was used as a protection.
  • The results showed that adriamycin chemotherapy increased the level of malondialdehyde (MDA), nitrogen oxide (NO) and decreased the activities of total superoxide dismutase (T-SOD), manganese superoxide dismutase (MnSOD), catalase (CAT), glutathione (GSH) and total antioxidant capacity (TAC).
  • Adriamycin chemotherapy also decreased the expression of Bcl-2, increased the expression of iNOS and cell apoptosis in the liver and kidney.
  • These data demonstrated that adriamycin chemotherapy could cause oxidative stress to the whole body, on which multiple antioxidants based on the theory of 'multiple antioxidant chain' had effective protection.
  • [MeSH-major] Antibiotics, Antineoplastic / toxicity. Antioxidants / therapeutic use. Carcinoma 256, Walker / drug therapy. Doxorubicin / toxicity. Liver Neoplasms / drug therapy
  • [MeSH-minor] Animals. Catalase / metabolism. Drug Therapy, Combination. Drugs, Chinese Herbal. Glutathione / metabolism. Kidney / drug effects. Kidney / metabolism. Lipid Peroxidation / drug effects. Liver / drug effects. Liver / metabolism. Longevity / drug effects. Malondialdehyde / metabolism. Medicine, Chinese Traditional. Nitric Oxide Synthase Type II / metabolism. Nitrogen Dioxide / metabolism. Oxidative Stress / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley. Superoxide Dismutase / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Nitrogen dioxide .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582587.001).
  • [ISSN] 0260-437X
  • [Journal-full-title] Journal of applied toxicology : JAT
  • [ISO-abbreviation] J Appl Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antioxidants; 0 / Drugs, Chinese Herbal; 0 / Proto-Oncogene Proteins c-bcl-2; 4Y8F71G49Q / Malondialdehyde; 80168379AG / Doxorubicin; EC 1.11.1.6 / Catalase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, rat; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; S7G510RUBH / Nitrogen Dioxide
  •  go-up   go-down


19. Kurth AA, Kim SZ, Bauss F, Müller R, Hovy L: [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis]. Z Orthop Ihre Grenzgeb; 2000 Mar-Apr;138(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis].
  • [Transliterated title] Eine antiosteolytische Therapie bewahrt die Trabekelstruktur und die mechanischen Eigenschaften des Knochens in Tumorosteolysen.
  • PURPOSE OF THE STUDY: Little is known about the effect of a tumor on the trabecular architecture, therefore we employed an animal model for the assessment of bone quality in tumor osteolysis to determine the alterations of the trabecular architecture in tumor osteolysis and after an interventional treatment with a bisphosphonate.
  • METHODS: To assess the bone mass and the micro-architecture of the trabecular bone in tumor osteolysis we employed a micro-computed tomography system.
  • An interventional treatment of the animals with a bisphosphonate increased the bone mineral content, mechanical and architectural parameters compared to the non-treated, tumor-bearing animals.
  • CONCLUSIONS: These results clearly show a beneficial effect of an anti-osteolytic treatment with a bisphosphonate in regard of bone quality in tumor-induced osteolysis.
  • [MeSH-major] Bone Neoplasms / pathology. Bone and Bones / drug effects. Diphosphonates / pharmacology. Osteolysis / pathology
  • [MeSH-minor] Animals. Bone Density / drug effects. Bone Resorption / pathology. Carcinoma 256, Walker / pathology. Disease Models, Animal. Humans. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820881.001).
  • [ISSN] 0044-3220
  • [Journal-full-title] Zeitschrift für Orthopädie und ihre Grenzgebiete
  • [ISO-abbreviation] Z Orthop Ihre Grenzgeb
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


20. Piffar PM, Fernandez R, Tchaikovski O, Hirabara SM, Folador A, Pinto GJ, Jakobi S, Gobbo-Bordon D, Rohn TV, Fabrício VE, Moretto KD, Tosta E, Curi R, Fernandes LC: Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett; 2003 Nov 25;201(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats.
  • We examine the potential benefits of combination of different anabolic agents such as insulin and clenbuterol associated to prostaglandin synthesis inhibitor (naproxen) on tumor growth, cachexia and renal function in Walker 256 tumor-bearing rats (WK).
  • Treatment begins at the 4th day after tumor inoculation, at the 14th day they were killed, glycemia, lacticidemia, glycogen content from liver, soleus and gastrocnemius muscles, tumor mass, body weight and kidney function were determined.
  • Tumor weight was significantly reduced by the different treatments.
  • Naproxen treatment (WK N) induced an increased by 14%.
  • [MeSH-major] Cachexia / drug therapy. Carcinoma 256, Walker / drug therapy. Clenbuterol / therapeutic use. Insulin / therapeutic use. Naproxen / therapeutic use
  • [MeSH-minor] Adrenergic beta-Agonists / therapeutic use. Animals. Blood Glucose / analysis. Body Weight / drug effects. Cyclooxygenase Inhibitors / therapeutic use. Drug Therapy, Combination. Eating / drug effects. Energy Intake. Glycogen / metabolism. Kidney / drug effects. Kidney / pathology. Liver / drug effects. Liver / pathology. Muscle, Skeletal / drug effects. Muscle, Skeletal / pathology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NAPROXEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14607327.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Blood Glucose; 0 / Cyclooxygenase Inhibitors; 0 / Insulin; 57Y76R9ATQ / Naproxen; 9005-79-2 / Glycogen; XTZ6AXU7KN / Clenbuterol
  •  go-up   go-down


21. Liu X, Heng WS, Paul, Li Q, Chan LW: Novel polymeric microspheres containing norcantharidin for chemoembolization. J Control Release; 2006 Nov;116(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemoembolization has been found to be a potentially effective method of treating certain types of cancer.
  • Norcantharidin, which possesses anti-tumor properties, was used to investigate the application of drug-containing microspheres for chemoembolization.
  • The growth inhibitory effect was concentration and time dependent.
  • These microspheres also exhibited excellent embolization and therapeutic effects on rats with transplanted tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Bicyclo Compounds, Heterocyclic / administration & dosage. Bicyclo Compounds, Heterocyclic / pharmacology. Chemoembolization, Therapeutic
  • [MeSH-minor] Alginates. Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Cell Line, Tumor. Drug Delivery Systems. Humans. Kinetics. Lactic Acid. Liver Neoplasms, Experimental / drug therapy. Liver Neoplasms, Experimental / pathology. Male. Microscopy, Electron, Scanning. Microspheres. Neoplasm Transplantation. Particle Size. Polyglycolic Acid. Polymers. Rats. Rats, Sprague-Dawley. Solubility. Survival

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050026.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Alginates; 0 / Antineoplastic Agents; 0 / Bicyclo Compounds, Heterocyclic; 0 / Polymers; 0 / polylactic acid-polyglycolic acid copolymer; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid; 5442-12-6 / norcantharidin
  •  go-up   go-down


22. Zalietok SP, Orlovs'kyĭ OA, Hohol' SV, Samoĭlenko OA, Hulua L, Kvesitadze HI: [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats]. Lik Sprava; 2006 Dec;(8):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats].
  • Green tea biocomposite had effectivey hampered the growth of rat Walker W-256 carcinoma and in less extent rat Guerin's carcinoma.
  • Black tea biocomposite had not practically influenced on Guerin's carcinoma growth.
  • The biocomposite from green tea and extract from red vine rind and lemon suppressed at the level of tendency the growth of rat Walker W-256 carcinoma.
  • The biocomposite from green tea and extract from red vine rind had hampered only Guerin's carcinoma growth and at the tendency had increased the growth of W-256 carcinosarcoma growth.
  • This biocomposite increased also considerably the therapeutic efficiency of cisplatin on Guerin's carcinoma.

  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427433.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Alves AP, Pessoa Cdo O, Costa-Lotufo L, Moraes Filho MO: Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma. Acta Cir Bras; 2007 Nov-Dec;22(6):457-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma.
  • PURPOSE: To investigate the effects of bisphosphosnate alendronate (ALD) and metotrexate (MTX) on an experimental model of Walker 256 carcinosarcoma developed in the oral cavity of rats.
  • METHODS Walker 256 carcinosarcoma cell suspension (0,1 mL) containing 10(6) cell/mL was implanted in the alveoli of the first and second molars.
  • CONCLUSION: The bisphosphonate alendronate exherted an osteoprotective effect and induced bone neoformation on the Walker 256 carcinosarcoma inoculated in rat mandibles.
  • The combination of metotrexate with bisphosphonate alendronate is more successful than treatment with the agents alone in controlling the growth of neoplastic cells and in stimulating reactive new bone.
  • Therefore, this may be an alternative treatment to malignant lesions of maxillaries with osteolysis.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235934.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; X1J18R4W8P / Alendronate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Wu HP, Feng GS, Liang HM, Zheng CS, Li X: Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol; 2004 Mar 15;10(6):813-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Transcatheter arterial embolization (TAE) of the hepatic artery has been accepted as an effective treatment for unresectable hepatocellular carcinoma (HCC).
  • This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer.
  • METHODS: VEGF antisense ODNs and sense ODNs were added to the media of non-serum cultured Walker-256 cells.
  • Thirty Walker-256 cell implanted rat liver tumor models were divided into 3 groups.
  • Volumes of tumors were measured by MRI before and 7 d after the treatment.
  • VEGF mRNA in cancerous and peri-cancerous tissues was detected by RT-PCR.
  • RESULTS: Antisense ODNs inhibited Walker-256 cells' VEGF expression.
  • VEGF mRNAs in cancerous and peri-cancerous tissues were expressed highest in LP group and lowest in LP+ODNs group.
  • CONCLUSION: VEGF antisense ODNs can inhibit VEGF expression of Walker-256 cells.
  • It may be an antiangiogenesis therapy agent for malignant tumors.
  • [MeSH-major] Embolization, Therapeutic. Iodized Oil / therapeutic use. Liver Neoplasms / blood supply. Oligonucleotides, Antisense / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15040023.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Vascular Endothelial Growth Factor A; 8001-40-9 / Iodized Oil
  • [Other-IDs] NLM/ PMC4727012
  •  go-up   go-down


25. Stepensky D, Golomb G, Hoffman A: Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci; 2002 Feb;91(2):508-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two rat models of bone disease were applied.
  • Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy.
  • Higher amounts of alendronate were found in bones and in internal organs after bolus drug administration as compared with continuous infusion.
  • Drug effects on plasma calcium levels and on urine calcium excretion were similar in both modes of alendronate administration.
  • [MeSH-minor] Animals. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / urine. Bone Resorption / drug therapy. Calcium / blood. Calcium / urine. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Carcinoma 256, Walker / urine. Drug Administration Schedule. Drug Evaluation, Preclinical / methods. Female. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / urine. Male. Neoplasm Transplantation. Parathyroidectomy. Rats. Rats, Sprague-Dawley. Rats, Wistar. Thyroidectomy. Tibia / pathology

  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:508-516, 2002
  • (PMID = 11835209.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


26. Sugahara S, Okuno S, Yano T, Hamana H, Inoue K: Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol Pharm Bull; 2001 May;24(5):535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting.
  • Using the Walker 256 model for carcinosarcoma-bearing rats, we intravenously administered 5 polysaccharide carriers with various molecular weights (MWs) and electric charges and tested for their plasma and tissue distribution.
  • As for the anionic charge, CMDex (110-180 kDa) with a degree of substitution (DS) of the CM groups ranging from 0.2 to 0.6, showed maximum plasma AUC values.
  • Doxorubicin (DXR) was bound to these carriers via a peptide spacer, GlyGlyPheGly (GGFG), to give carrier-GGFG-DXR conjugates (DXR content: 4.2-7.0 (w/w)%), and the antitumor effects of these conjugates were tested with Walker 256 carcinosarcoma-bearing rats by monitoring the tumor weights after a single intravenous injection.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers. Polysaccharides / pharmacokinetics
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Doxorubicin / administration & dosage. Female. Molecular Weight. Rats. Rats, Wistar. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379776.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Polysaccharides; 80168379AG / Doxorubicin
  •  go-up   go-down


27. Tao K, Chen D, Tian Y, Wu Z: [The cytotoxic effects of the adriamycin magnetic albumin microspheres combined with external magnetic fields on the malignant tumor cells]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2001 Jun;18(2):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study sought to assess the inhibitory effects of the adriamycin magnetic albumin microspheres (ADM-MAMs) on Walker-256 malignant tumor cells in vitro induced by the permanent magnetic fields.
  • The cultured Walker-256 cells were divided into three groups; the group of ADM-MAMs combined with magnetic fields, the group of AMD-MAMs without magnetic fields, and ADM group.
  • [MeSH-major] Albumins. Carcinoma 256, Walker / pathology. Doxorubicin / pharmacology. Magnetics / therapeutic use
  • [MeSH-minor] Animals. Cell Size / drug effects. Cell Size / radiation effects. Combined Modality Therapy. Microspheres. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / radiation effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450539.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 80168379AG / Doxorubicin
  •  go-up   go-down


28. Yin Q, Cheng W, Cheng MY, Fan SZ, Shen W: Intrathecal injection of anti-CX3CR1 neutralizing antibody delayed and attenuated pain facilitation in rat tibial bone cancer pain model. Behav Pharmacol; 2010 Oct;21(7):595-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syngeneic Walker 256 mammary gland carcinoma cells were injected into the tibia medullary cavity to establish the rat model of bone cancer pain.
  • [MeSH-major] Antibodies, Neutralizing. Bone Neoplasms / complications. Carcinoma 256, Walker / complications. Pain / immunology. Pain Management. Receptors, Chemokine / immunology
  • [MeSH-minor] Animals. Disease Models, Animal. Hyperalgesia / physiopathology. Hyperalgesia / therapy. Injections, Spinal. Molecular Targeted Therapy / trends. Pain Measurement / drug effects. Pain Measurement / psychology. Pain Threshold / drug effects. Pain Threshold / psychology. Rats. Rats, Sprague-Dawley. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736819.001).
  • [ISSN] 1473-5849
  • [Journal-full-title] Behavioural pharmacology
  • [ISO-abbreviation] Behav Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neutralizing; 0 / CX3CR1 protein, rat; 0 / Receptors, Chemokine
  •  go-up   go-down


29. Wyld L, Reed MW, Brown NJ: Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer; 2001 May 18;84(10):1384-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cell death response to photodynamic therapy is dependent on dose and cell type.
  • PDT-induced cell death, by either apoptosis or necrosis may vary with cell type or PDT dose.
  • 5 cell types were treated with varying doses of aminolaevulinic acid-induced PDT and the type of cell death analysed.
  • The mode of cell death was found to depend on both cell type and light dose.
  • [MeSH-major] Cell Death / drug effects. Endothelium, Vascular / cytology. Photochemotherapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Breast Neoplasms. Carcinoma 256, Walker. Cells, Cultured. Dose-Response Relationship, Drug. Female. Genes, p53. Humans. Rats. Tumor Cells, Cultured. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Oncol Res. 1994;6(12):569-79 [7787250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5241-6 [8643560.001]
  • [Cites] Cytometry. 1997 May 1;28(1):11-24 [9136751.001]
  • [Cites] Int J Cancer. 1998 Apr 13;76(2):259-66 [9537589.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):823-30 [8167895.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 10;1366(1-2):151-65 [9714783.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):72-81 [10408696.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9357-60 [9545256.001]
  • (PMID = 11355951.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ PMC2363631
  •  go-up   go-down


30. Novaes MR, Lima LA, Novaes LC, Souza MV: Metabolic and hematological effects of dietary supplementation with arginine on rats bearing ascitic Walker 256 tumor. Ann Nutr Metab; 2004 Nov-Dec;48(6):404-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic and hematological effects of dietary supplementation with arginine on rats bearing ascitic Walker 256 tumor.
  • The aim of the present study is to evaluate the effects of dietary supplementation with arginine on metastatic dissemination, amino acid metabolism, hematological functions of rats with Walker 256 ascitic tumor.
  • The findings suggest that arginine supplementation at 6% may have a beneficial effect on to the host, besides its pharmacological action.
  • [MeSH-major] Amino Acids / metabolism. Arginine / metabolism. Arginine / therapeutic use. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Dietary Supplements. Disease Models, Animal. Dose-Response Relationship, Drug. Humans. Male. Neoplasm Metastasis / drug therapy. Random Allocation. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15583469.001).
  • [ISSN] 0250-6807
  • [Journal-full-title] Annals of nutrition & metabolism
  • [ISO-abbreviation] Ann. Nutr. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Amino Acids; 94ZLA3W45F / Arginine
  •  go-up   go-down


31. Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG: Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg; 2006 May;10(5):689-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to determine the effect, if any, on survival of adjuvant 5-FU-based chemoradiotherapy following pancreaticoduodenectomy for pancreatic carcinoma.
  • Five prospective studies (4 level I, 1 level II) with a total of 607 (229 surgery only; 378 surgery-adjuvant) patients followed for survival met selection criteria.
  • Using a fixed effects model, the summary estimate showed an absolute 2-year survival benefit with adjuvant therapy of 12% (95% CI, 3%-21%, P = 0.011).
  • Trials after 1997 (n = 3) indicated a survival benefit of 8% to patients receiving adjuvant therapy (95% CI, -3-18%, P = 0.145).
  • Summary estimates were unchanged when the analysis was performed with a random effects model.
  • 5-FU based chemotherapy with radiotherapy given after resection imparts a small overall survival benefit of 2 years.
  • The benefit of 5-FU-based adjuvant therapy, however, has declined in recent years, and its significance remains unproven in the context of current diagnostic and surgical practice.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / therapy. Fluorouracil / therapeutic use. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Humans. Neoadjuvant Therapy. Prospective Studies. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1305-10 [12654442.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Onkologie. 2000 Dec;23(6):597-602 [11441269.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):974-80 [12829132.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):256-60 [14648783.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Am J Surg. 2000 May;179(5):367-71 [10930481.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 1979 Feb;189(2):205-8 [426553.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):3-9 [12826245.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):587-98 [12127126.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):806-13 [12454519.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35 [11309645.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):75-81 [11986021.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2805-13 [12926117.001]
  • (PMID = 16713541.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Dubin M, Fernandez Villamil SH, Stoppani AO: [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires); 2001;61(3):343-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
  • [Transliterated title] Citotoxicidad de la beta-lapachona: una o-naftoquinona con posibles usos terapéuticos.
  • Initial observations proved its capability for inhibiting growth of Yoshida tumor and Walker 256 carcinosarcoma. beta-Lap redox-cycling in the presence of reductants and oxygen yields "reactive oxygen species" (ROS: O2-, OH and H2O2) which cytotoxicity led to assume its role in beta-lap activity in cells. beta-Lap inhibited DNA synthesis in Trypanosoma cruzi as well as topoisomerases I and II, poly(ADP-ribose) polymerase (PARP) in different cells.
  • These enzymes are essential for maintaining DNA structure. beta-Lap inhibited growth of a large variety of tumor cells including epidermoid laringeal cancer, prostate, colon, ovary and breast cancer and also different types of leukemia cells.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology. Neoplasms / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / physiology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / enzymology. Humans. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / enzymology. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474885.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Topoisomerase I Inhibitors; 4707-32-8 / beta-lapachone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 58
  •  go-up   go-down


33. Clichici S, Filip A, Daicoviciu D, Ion RM, Mocan T, Tatomir C, Rogojan L, Olteanu D, Muresan A: The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin. Acta Physiol Hung; 2010 Mar;97(1):41-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin.
  • Photodynamic therapy (PDT) is a promising therapy especially in skin cancer, using the systemic administration of a photosensitizer (PS), followed by the local irradiation of the tumor with visible light.
  • Our study evaluates the effects of PDT with TSPP upon the tumor levels of ROS and upon the metalloproteinases 2 (MMP2) activities on Wistar male rats bearing 256 Walker carcinosarcoma in correlation with the accumulation of PS in the tumor and with the intratumor histological alterations.
  • Our results emphasize that 24 hours after the PDT with TSPP, the ROS generation increases, as revealed by protein carbonyls and malondialdehyde levels and the antioxidant capacity (hydrogen donors, thiol groups) decreases in the tumor tissue.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Photochemotherapy. Porphyrins / therapeutic use. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Animals. Antioxidants / metabolism. Kinetics. Male. Matrix Metalloproteinase 2 / metabolism. Oxidative Stress / drug effects. Photosensitizing Agents / pharmacology. Photosensitizing Agents / therapeutic use. Rats. Rats, Wistar. Time Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233689.001).
  • [ISSN] 0231-424X
  • [Journal-full-title] Acta physiologica Hungarica
  • [ISO-abbreviation] Acta Physiol Hung
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Reactive Oxygen Species; 35218-75-8 / tetraphenylporphine sulfonate; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


34. Harano N, Ono K, Hidaka K, Kai A, Nakanishi O, Inenaga K: Differences between orofacial inflammation and cancer pain. J Dent Res; 2010 Jun;89(6):615-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this question, we compared the effects of an anti-inflammatory drug, indomethacin, on pain and neurochemical changes in the medullary dorsal horn in orofacial inflammation and cancer models.
  • The same procedure suppressed allodynia and hyperalgesia in the cancer model, but the suppression was weak when compared with that in the inflammation model.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Facial Neoplasms / physiopathology. Facial Pain / physiopathology. Indomethacin / therapeutic use
  • [MeSH-minor] Animals. Calcitonin Gene-Related Peptide / analysis. Calcitonin Gene-Related Peptide / drug effects. Carcinoma 256, Walker / physiopathology. Disease Models, Animal. Galanin / analysis. Galanin / drug effects. Hot Temperature. Hyperalgesia / drug therapy. Hyperalgesia / physiopathology. Inflammation / physiopathology. Injections, Intraperitoneal. Male. Neuropeptides / analysis. Neuropeptides / drug effects. Neurotransmitter Agents / analysis. Pain Threshold / drug effects. Pain Threshold / physiology. Physical Stimulation. Rats. Rats, Wistar. Reaction Time / drug effects. Reaction Time / physiology. Substance P / analysis. Substance P / drug effects. Touch. Trigeminal Caudal Nucleus / drug effects. Trigeminal Caudal Nucleus / physiopathology. Vibrissae

  • Hazardous Substances Data Bank. INDOMETHACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332329.001).
  • [ISSN] 1544-0591
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Neuropeptides; 0 / Neurotransmitter Agents; 33507-63-0 / Substance P; 83652-28-2 / Calcitonin Gene-Related Peptide; 88813-36-9 / Galanin; XXE1CET956 / Indomethacin
  •  go-up   go-down


35. Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T, Kuroi K, Matsumoto G, Toi M, Nakashima E: Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells. Oncology; 2009;77(3-4):182-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC.
  • METHODS: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME).
  • RESULTS: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC(50) values for TR-BME were higher than those for TR-BBB or Walker 256.
  • Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC(50).
  • In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Endothelial Cells / drug effects. Paclitaxel / pharmacology. Stem Cells / drug effects. Taxoids / pharmacology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Cell Line. Cell Migration Inhibition / drug effects. Cell Proliferation / drug effects. Female. Humans. Neovascularization, Pathologic / drug therapy. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19729975.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


36. Kolganov AS: [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia]. Vopr Onkol; 2001;47(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia].
  • [Transliterated title] Eksperimental'naia khimioterapiia zlokachestvennykh opukholeĭ v sochetanii s kratkovremennoĭ obshcheĭ gipoksieĭ.
  • The effect of hypoxy on chemotherapy with emoxyl, 5-fluorouracil and bleomycin which are characterized by different affinities with oxygen has been investigated.
  • In an experiment using 96 rats, each weighing 180 g, subcutaneously inoculated with Walker's carcinosarcoma and carcinoma.
  • PC-1, combined use of chemotherapy and hypoxy was followed by a significant inhibition of tumor growth rate, against a background of significant drop in survival due to the increased toxic effect of the drugs.
  • Therefore, hypoxy cannot be recommended for modifying chemotherapy of tumors irrespective of drug affinity with oxygen.
  • [MeSH-major] Anoxia. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Carcinoma 256, Walker / therapy. Daunorubicin / analogs & derivatives. Daunorubicin / therapeutic use

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317544.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 84412-94-2 / Emoxyl; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down






Advertisement